603127 昭衍新药
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-0.8644.82314.02413.33530.369
总资产报酬率 ROA (%)-0.7193.89411.36710.47417.738
投入资产回报率 ROIC (%)-0.7434.08911.93211.01722.796

边际利润分析
销售毛利率 (%)27.48042.61747.89848.73351.381
营业利润率 (%)-5.21721.33854.04142.38833.564
息税前利润/营业总收入 (%)-10.82514.97447.85441.06733.744
净利润/营业总收入 (%)-5.56116.47647.32036.68629.150

收益指标分析
经营活动净收益/利润总额(%)-153.696148.82668.48466.93175.325
价值变动净收益/利润总额(%)227.180-46.55629.24127.22416.770
营业外收支净额/利润总额(%)0.331-0.0291.158-0.138-0.151

偿债能力分析
流动比率 (X)4.1074.8543.2154.7891.556
速动比率 (X)2.8513.5842.0254.2121.022
资产负债率 (%)16.10817.41420.97016.31341.923
带息债务/全部投入资本 (%)11.14311.43512.76211.42128.958
股东权益/带息债务 (%)774.583749.269657.404757.156226.434
股东权益/负债合计 (%)521.552474.155376.548512.423138.617
利息保障倍数 (X)1.936-2.355-7.016-32.515146.543

营运能力分析
应收账款周转天数 (天)42.37230.71024.36923.31732.663
存货周转天数 (天)487.278535.589441.019256.218214.447